These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 36198259)
1. The Value of Sacubitril/Valsartan in Acute Anterior Wall ST-Segment Elevation Myocardial Infarction before Emergency Percutaneous Coronary Intervention. Lin G; Chen W; Wu M; Dai C; Xu K Cardiology; 2022; 147(5-6):479-485. PubMed ID: 36198259 [TBL] [Abstract][Full Text] [Related]
2. Improved heart function and cardiac remodelling following sacubitril/valsartan in acute coronary syndrome with HF. Liu H; Su Y; Shen J; Jiao Y; Li Y; Liu B; Hou X; Jin Q; Chen Y; Sun Z; Xi Q; Feng B; Fu Z ESC Heart Fail; 2024 Apr; 11(2):937-949. PubMed ID: 38224955 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction. Rezq A; Saad M; El Nozahi M Am J Cardiol; 2021 Mar; 143():7-13. PubMed ID: 33417876 [TBL] [Abstract][Full Text] [Related]
4. The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Gu J; Wang Y; Wang CQ; Zhang JF Eur J Intern Med; 2023 Jun; 112():62-69. PubMed ID: 36990878 [TBL] [Abstract][Full Text] [Related]
5. Rationale and design of a multi-center, prospective randomized controlled trial on the effects of sacubitril-valsartan versus enalapril on left ventricular remodeling in ST-elevation myocardial infarction: The PERI-STEMI study. Diao K; Wang D; Chen Z; Wu X; Ma M; Zhu Y; Zhang L; Wang H; Wang M; He S; Li C; Deng Q; Yan T; Wu T; Tang L; Huang B; Sun J; He Y Clin Cardiol; 2021 Dec; 44(12):1709-1717. PubMed ID: 34668596 [TBL] [Abstract][Full Text] [Related]
6. Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI). Chen C; Wu X; Li Y; Peng Y Ann Palliat Med; 2021 May; 10(5):5455-5461. PubMed ID: 34044572 [TBL] [Abstract][Full Text] [Related]
7. Benefits of early administration of Sacubitril/Valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention. Zhang Y; Wu Y; Zhang K; Ke Z; Hu P; Jin D Coron Artery Dis; 2021 Aug; 32(5):427-431. PubMed ID: 32868662 [TBL] [Abstract][Full Text] [Related]
8. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF. Myhre PL; Prescott MF; Murphy SP; Fang JC; Mitchell GF; Ward JH; Claggett B; Desai AS; Solomon SD; Januzzi JL JACC Heart Fail; 2022 Feb; 10(2):119-128. PubMed ID: 35115085 [TBL] [Abstract][Full Text] [Related]
9. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study. Pascual-Figal D; Wachter R; Senni M; Bao W; Noè A; Schwende H; Butylin D; Prescott MF; JACC Heart Fail; 2020 Oct; 8(10):822-833. PubMed ID: 32800508 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic effects and safety of early use of sacubitril/valsartan after acute myocardial infarction: a systematic review and meta-analysis. Zhang L; Yan K; Zhao H; Shou Y; Chen T; Chen J Ann Palliat Med; 2022 Mar; 11(3):1017-1027. PubMed ID: 35365031 [TBL] [Abstract][Full Text] [Related]
11. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR; JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839 [TBL] [Abstract][Full Text] [Related]
12. Predictors of in-hospital heart failure in patients with acute anterior wall ST-segment elevation myocardial infarction. Liang J; Zhang Z Int J Cardiol; 2023 Mar; 375():104-109. PubMed ID: 36638919 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction - Results From the PARALLEL-HF Study. Tsutsui H; Momomura SI; Saito Y; Ito H; Yamamoto K; Sakata Y; Desai AS; Ohishi T; Iimori T; Kitamura T; Guo W; Circ J; 2021 Apr; 85(5):584-594. PubMed ID: 33731544 [TBL] [Abstract][Full Text] [Related]
14. Long-Term Mortality and Morbidity Related to Congestive Heart Failure with Reduced Ejection Fraction (CHFrEF) in Palestinian Patients Maintained on Submaximal Sacubitril/Valsartan Doses: A Pilot Study. Aqel R; Alzughayyar TZ; Abukhalaf SA; Misk RA; Zalloum JS J Renin Angiotensin Aldosterone Syst; 2021; 2021():1829873. PubMed ID: 35027945 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study. Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961 [TBL] [Abstract][Full Text] [Related]